Featured Posts
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
News Release
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Search Posts
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. FINANCE The Securities and Exchange Commission may ease corporate accounting regulations on small public…
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. ENERGY Many of the hurricane-damaged energy facilities in the Gulf Coast are still offline. CEI…
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. LEGAL Congress considers the question of what can be done with copyrighted material whose owner cannot…
Op-Eds
EPA Whips Up Air Pollution Scare
The air pollution scare industry is at it again — in a very timely manner to help the Environmental Protection Agency impose more dubious…
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. BUSINESS AT&T announces a merger with BellSouth, pending approval by the FCC and U.S. Justice Department.
Op-Eds
Patients vs. Paternalism
Decisions about drug safety and efficacy are far from easy. Tysabri, a multiple sclerosis (MS) drug that was voluntarily withdrawn from the market last year…